| P50 | author | Katarzyna Gawlik | Q90469669 |
| P2093 | author name string | Udayan Chatterji | |
| | Philippe Gallay | |
| | Michael Bobardt | |
| | Precious Lim | |
| P2860 | cites work | Completion of the entire hepatitis C virus life cycle in genetically humanized mice | Q37382399 |
| | Development of novel antiviral therapies for hepatitis C virus | Q37801585 |
| | New direct-acting antivirals in the development for hepatitis C virus infection | Q37823323 |
| | New hepatitis C therapies in clinical development | Q37911056 |
| | Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors. | Q37940114 |
| | Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents | Q37968485 |
| | Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein | Q38321693 |
| | The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection | Q39378324 |
| | Cyclophilin, a primary molecular target for cyclosporine. Structural and functional implications | Q39516228 |
| | Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase | Q40858827 |
| | HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors | Q40998392 |
| | New antiviral agents for hepatitis C | Q42105512 |
| | Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group | Q42984733 |
| | The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. | Q43046668 |
| | A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. | Q43048199 |
| | The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. | Q48033815 |
| | Polyinosinic-cytidylic acid complex (poly I:C) and viral infections in mice. | Q54062493 |
| | Emerging drugs for hepatitis C | Q57271196 |
| | Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy | Q83263799 |
| | Epidemiology of hepatitis C virus infection | Q22305500 |
| | Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A | Q24303838 |
| | Curing a viral infection by targeting the host: the example of cyclophilin inhibitors | Q26828727 |
| | Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation | Q27469500 |
| | Robust hepatitis C virus infection in vitro | Q27470013 |
| | Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses | Q27473226 |
| | Visualization of Double-Stranded RNA in Cells Supporting Hepatitis C Virus RNA Replication | Q27485448 |
| | Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B | Q27488369 |
| | Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex | Q27488788 |
| | Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics | Q27489037 |
| | The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication | Q27489053 |
| | Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A | Q27491303 |
| | Global epidemiology of hepatitis C virus infection | Q27860799 |
| | Production of infectious hepatitis C virus in tissue culture from a cloned viral genome | Q27860899 |
| | Complete replication of hepatitis C virus in cell culture | Q27860934 |
| | Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes | Q27861119 |
| | Hepatitis C virus controls interferon production through PKR activation | Q28473895 |
| | DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A | Q28748683 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Cyclophilin inhibitors for the treatment of HCV infection. | Q30318599 |
| | Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins | Q33711743 |
| | Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A | Q33987197 |
| | Epidemiology of hepatitis C virus (HCV) infection | Q33995067 |
| | Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation | Q34000124 |
| | Profile of alisporivir and its potential in the treatment of hepatitis C. | Q34329744 |
| | Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A. | Q35063336 |
| | American Gastroenterological Association technical review on the management of hepatitis C. | Q36364156 |
| | Treating viral hepatitis C: efficacy, side effects, and complications | Q36564615 |
| | Mechanism of interferon action: evidence for intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA-dependent protein kinase PKR | Q36655674 |
| | Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activities | Q36656593 |
| | Current and future management of chronic hepatitis C infection | Q37143005 |
| P304 | page(s) | 1-8 | |
| P577 | publication date | 2014-03-07 | |
| P1433 | published in | The open virology journal | Q27722048 |
| P1476 | title | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells | |
| P478 | volume | 8 | |